A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
Recruiting · NCT03424005 · Interventional (participants receive a specific treatment) · Lead sponsor: Hoffmann-La Roche
View the official record on ClinicalTrials.gov →Interventions studied
AbemaciclibAtezolizumabAtirmociclibBevacizumabCapecitabineChemotherapy (Gemcitabine + Carboplatin or Eribulin)EmpagliflozinFulvestrantGiredestrantInavolisib (Dose #1)Inavolisib (Dose #2)IpatasertibLetrozoleMetforminNab-PaclitaxelPalbociclibRibociclib (Dose #1)Ribociclib (Dose #2)SGN-LIV1ASacituzumab GovitecanSelicrelumabTocilizumabTrastuzumab Deruxtecan
What this trial is about
This is an umbrella study evaluating the efficacy and safety of multiple treatment combinations in participants with metastatic or inoperable locally advanced breast cancer. The study will be performed in two stages. During Stage 1, seven cohorts will be enrolled in parallel in this study: Cohort 1 will consist of programmed death-ligand 1 (PD-L1)-positive participants who have received no prior systemic therapy for metastatic or inoperable locally advanced triple-negative breast cancer (TNBC) (first-line \[1L\] PD-L1+ cohort). Cohort 2 will consist of participants who had disease progression during or following 1L treatment with chemotherapy for metastatic or inoperable locally-advanced TNBC and have not received cancer immunotherapy (CIT) (second-line \[2L\] CIT-naïve cohort). Cohort 3, 5, 6 and 7 will consist of participants with locally advanced or metastatic hormone receptor-positive (HR+), human epidermal growth factor receptor 2 (HER2)-negative disease with one or more PIK3CA mutations. Cohort 4 will consist of participants with locally advanced or metastatic HER2+ /HER2-low disease with one or more PIK3CA mutations who had disease progression on standard-of-care therapies (HER2+ /HER2-low cohort). In each cohort, eligible participants will initially be assigned to one of several treatment arms (Stage 1). During Stage 2, participants in the 2L CIT-naïve cohort who experience disease progression, loss of clinical benefit, or unacceptable toxicity during Stage 1 may be eligible to continue treatment with a different treatment combination, provided Stage 2 is open for enrollment and all eligibility criteria are met.
Who can take part
Age range
18 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Phase 1, Phase 2
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Patients must meet all of the following criteria to qualify for Stage 1 (all cohorts) and to qualify for Stage 2 (2L CIT-naïve cohort):
- Age \>/= 18 years at the time of signing Informed Consent Form
- Eastern cooperative oncology group (ECOG) performance status of 0 or 1
- Able to comply with the study protocol, in the investigator's judgment
- Metastatic or inoperable locally advanced adenocarcinoma of the breast
- Measurable disease (at least one target lesion) according to RECIST v1.1
- Life expectancy \>/= 3 months, as determined by the investigator
- Tumor accessible for biopsy, unless archival tissue is available
- Availability of a representative tumor specimen that is suitable for biomarker analysis via central testing
- Adequate hematologic and end-organ function, defined by the following laboratory test results, obtained within 14 days prior to initiation of study treatment
- For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures and agreement to refrain from breastfeeding and donating eggs, as outlined for each specific treatment arm
- For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive measures, and agreement to refrain from donating sperm, as outlined for each specific treatment arm
Exclusion criteria
- Exclusion Criteria for Stage 1
- Prior treatment with T-cell co-stimulating or immune checkpoint blockade therapies, including anti-CTLA-4, anti-PD-1, and anti-PD-L1 therapeutic antibodies, CD40 agonists or interleukin-2 (IL-2) or IL-2-like compounds
- Biologic treatment (e.g., bevacizumab) within 2 weeks prior to initiation of study treatment, or other systemic treatment for TNBC within 2 weeks or 5 half-lives of the drug (whichever is longer) prior to initiation of study treatment
- Treatment with systemic immunosuppressive medication (including, but not limited to, corticosteroids, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor alpha agents) within 2 weeks prior to initiation of study treatment, or anticipation of need for systemic immunosuppressive medication during the course of the study
- Eligibility only for the control arm
- Exclusion Criteria for Stage 1 (both cohorts) and Stage 2 (2L CIT-naïve cohort)
- Adverse events from prior anti-cancer therapy that have not resolved to Grade \</= 1 or better with the exception of alopecia of any grade and Grade \</= 2 peripheral neuropathy
- Treatment with investigational therapy within 28 days prior to initiation of study treatment
- Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures (once monthly or more frequently)
- Uncontrolled tumor-related pain
- Symptomatic, untreated, or actively progressing central nervous system (CNS) metastases
- History of leptomeningeal disease
- Active or history of autoimmune disease or immune deficiency
- History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan. History of radiation pneumonitis in the radiation field (fibrosis) is permitted.
- Active tuberculosis
- Severe infection within 4 weeks prior to initiation of study treatment
- Treatment with therapeutic oral or IV antibiotics within 2 weeks prior to initiation of study treatment
- Significant cardiovascular disease
- Prior allogeneic stem cell or solid organ transplantation
- History of malignancy other than breast cancer within 2 years prior to screening, with the exception of those with a negligible risk of metastasis or death
- Pregnancy or breastfeeding, or intention of becoming pregnant during the study
Where it is running
53 locations listed across 12 US states.
- City of Hope - Duarte - Duarte, California, United States
- City of Hope - Duarte, California, United States
- City of Hope - Orange County Lennar Foundation Cancer Center - Irvine, California, United States
- University of California San Diego (UCSD) - Koman Family Outpatient Pavilion ? La Jolla - La Jolla, California, United States
- University of California San Diego Medical Center - La Jolla, California, United States
- UCLA Health 200 Medical Plaza - Los Angeles, California, United States
- Stanford Cancer Institute - Stanford, California, United States
- Rocky Mountain Cancer Center - Longmont - Longmont, Colorado, United States
- H. Lee Moffitt Cancer Center and Research Inst. - Tampa, Florida, United States
- City of Hope® Cancer Center Chicago - Zion, Illinois, United States
- Metro-Minnesota Community Oncology Research Consortium - Saint Paul, Minnesota, United States
- Renown Regional Medical Center - Reno, Nevada, United States
- Hackensack Univ Medical Center - Hackensack, New Jersey, United States
- Regional Cancer Care Associates, LLC - Howell Township, New Jersey, United States
- Rutgers Cancer Institute of New Jersey - New Brunswick, New Jersey, United States
- NYU Langone Medical Center - New York, New York, United States
- Duke Cancer Institute - Durham, North Carolina, United States
- Thomas Jefferson University Hospital - Philadelphia, Pennsylvania, United States
- University of Pittsburgh Medical Center - Pittsburgh, Pennsylvania, United States
- Tennessee Oncology - Chattanooga Oncology & Hematology Associates - Chattanooga, Tennessee, United States
- The West Clinic - Germantown, Tennessee, United States
- Tennessee Oncology PLLC - Nashville, Tennessee, United States
- Vanderbilt University Medical Center - Nashville, Tennessee, United States
- Texas Oncology-Plano East - Plano, Texas, United States
- Hospital del Mar - Barcelona, Spain
- Vall d?Hebron Institute of Oncology (VHIO), Barcelona - Barcelona, Spain
- Universitätsklinikum Erlangen - Erlangen, Germany
- Universitätsklinikum Essen - Essen, Germany
- Beatson West of Scotland Cancer Centre - Glasgow, United Kingdom
- National Cancer Center Clinical Trials Center / Center for Breast Cancer - Goyang-si, South Korea
- Rambam Medical Center - Haifa, Israel
- Shaare Zedek Medical Center - Jerusalem, Israel
- Hadassah University Medical Center - Jerusalem, Israel
- Barts Health NHS Trust - St Bartholomew's Hospital - London, United Kingdom
- Centre Léon Bérard - Lyon, France
- Hospital Universitario Ramon y Cajal - Madrid, Spain
- Centro Integral Oncológico Clara Campal Ensayos Clínicos START - Madrid, Spain
- Institut régional du Cancer Montpellier - Montpellier, France
- Rabin MC - Petah Tikva, Israel
- Sheba Medical Center - Ramat Gan, Israel
- Seoul National University Hospital - Seoul, South Korea
- Severance Hospital - Seoul, South Korea
- Asan Medical Center - Seoul, South Korea
- Samsung Medical Center - Seoul, South Korea
- National Cheng Kung University Hospital - Tainan, Taiwan
- National Taiwan University Hospital - Taipei, Taiwan
- Tel-Aviv Sourasky Medical Center - Tel Aviv, Israel
- Assuta Medical Centers - Tel Aviv, Israel
- Institut Universitaire du Cancer de Toulouse-Oncopole - Toulouse, France
- Gustave Roussy - Villejuif, France
- Hospital Universitario Virgen Macarena - Seville, Sevilla, Spain
- Peter MacCallum Cancer Centre-East Melbourne - Melbourne, Victoria, Australia
- Fiona Stanley Hospital - Medical Oncology - Murdoch, Western Australia, Australia